title: A pilot trial evaluating Meta050, a proprietary combination of reduced iso-alpha acids, rosemary extract and oleanolic acid in patients with arthritis and fibromyalgia.
abstract: The aim of this open-label, 8-week observational trial was to investigate the efficacy of Meta050 (a proprietary, standardized combination of reduced iso-alpha-acids from hops, rosemary extract and oleanolic acid) on pain in patients with rheumatic disease. Osteoarthritis, rheumatoid arthritis and fibromyalgia patients were given 440 mg Meta050 three times a day for 4 weeks, which was changed to 880 mg twice a day for the subsequent 4 weeks in the majority of patients. Pain and condition-specific symptoms were assessed using a standard visual analog scale (VAS), an abridged arthritis impact measurement scale (AIMS2) and the fibromyalgia impact questionnaire. Fifty-four subjects with rheumatic disease completed the trial. Following treatment, a statistically significant decrease in pain of 50% and 40% was observed in arthritis subjects using the VAS (p < 0.0001; Wilcoxon-ranked sums) and AIMS2 (p < 0.0001), respectively. Fibromyalgia subject scores did not significantly improve. A decreasing trend of C-reactive protein, a marker for inflammation, was also observed in those subjects who presented with elevated C-reactive protein. No serious side effects were observed. These observations suggest that Meta050 at a dosage of 440 mg three times a day has a beneficial effect on pain in arthritis subjects.
authors.affiliation: Clinical Research at the Functional Medicine Research Center, Gig Harbor, WA 98332, USA. DanLukaczer@metagenics.com
authors.forename: Daniel
authors.initials: D
authors.lastname: Lukaczer
authors.forename: Gary
authors.initials: G
authors.lastname: Darland
authors.forename: Matthew
authors.initials: M
authors.lastname: Tripp
authors.forename: DeAnn
authors.initials: D
authors.lastname: Liska
authors.forename: Robert H
authors.initials: RH
authors.lastname: Lerman
authors.forename: Barbara
authors.initials: B
authors.lastname: Schiltz
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Bland
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000473:pathology; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005356:Fibromyalgia / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D027582:Humulus; D008297:Male; D008875:Middle Aged; D031658:Olea; D009828:Oleanolic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D010003:Osteoarthritis / Q000188:drug therapy / Q000473:pathology; D010147:Pain Measurement; D008517:Phytotherapy; D010865:Pilot Projects; D010936:Plant Extracts / Q000008:administration & dosage / Q000627:therapeutic use*; D027542:Rosmarinus; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D010936:Plant Extracts; D009828:Oleanolic Acid